Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.4
3.9
Journals
JCM
Special Issues
Neuropsychopharmacology: Advances, Challenges and Opportunities
share announcement

Neuropsychopharmacology: Advances, Challenges and Opportunities

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Mental Health".

Deadline for manuscript submissions: 20 June 2024 | Viewed by 1340

Special Issue Editors

Dr. Qin Xiang Ng

E-Mail Website
Guest Editor
Health Services Research Unit, Singapore General Hospital, Singapore, Singapore
Interests: psychiatry; mood disorders; public health; systematic reviews; meta-analyses; evidence-based medicine
Prof. Dr. Keming Gao

E-Mail Website
Guest Editor
1. Department of Psychiatry, University Hospitals Cleveland Medical Center, Cleveland, OH 44106, USA
2. School of Medicine, Case Western Reserve University, Cleveland, OH 44106, USA
Interests: adult psychiatry; anxiety disorders; bipolar disorders research; mood disorders; phenomenology and psychopharmacotherapy

Special Issue Information

Dear Colleagues,

Over the past decade, we have witnessed promising advances in neuroscience and have acquired a greater ability to study human genomics, drug receptor activity, and neural circuitry in detail. However, the clinical translation of these findings has not been so successful.

This Special Issue is committed to the rapid publication of original research and review articles concerning all clinical and basic science aspects of neuropsychopharmacology and psychiatry. This includes research on the mechanisms by which drugs interact with the brain, and the behavioral and physiological outcomes of these interactions. 

Articles that advance our understanding of existing and novel neuropsychopharmacological agents or provide new insights into the biological basis of psychiatric disorders are particularly welcomed.

Dr. Qin Xiang Ng
Prof. Dr. Keming Gao
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • neuropsychopharmacology
  • mood disorders
  • bipolar disorder
  • major depressive disorder
  • psychosis
  • biological psychiatry

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

24 pages, 2847 KiB  
Article
Efficacy and Safety of Antidiabetic Agents for Major Depressive Disorder and Bipolar Depression: A Meta-Analysis of Randomized, Double-Blind, Placebo-Controlled Trials
by Jian Zhang, Rongyi Sun, Yang Cai, Bo Peng, Xi Yang and Keming Gao
J. Clin. Med. 2024, 13(4), 1172; https://doi.org/10.3390/jcm13041172 - 19 Feb 2024
Viewed by 895
Abstract
Background: This meta-analysis aimed to determine the efficacy and safety of antidiabetic agents in the treatment of major depressive disorder and bipolar depression. Methods: Randomized controlled trials (RCTs) of antidiabetic agents in major depressive disorder or bipolar depression were searched in three electronic [...] Read more.
Background: This meta-analysis aimed to determine the efficacy and safety of antidiabetic agents in the treatment of major depressive disorder and bipolar depression. Methods: Randomized controlled trials (RCTs) of antidiabetic agents in major depressive disorder or bipolar depression were searched in three electronic databases and three clinical trial registry websites from their inception up to October 2023. The differences in changes in the depression rating scale scores from baseline to endpoint or pre-defined sessions, response rate, remission rate, rate of side effects and dropout rate between antidiabetic agents and placebo were meta-analyzed. Results: Six RCTs involving 399 participants were included in the final meta-analysis, which did not find that antidiabetics outperformed the placebo in reducing depressive symptoms. The standardized mean difference (SMD) in the depression scores from baseline to endpoint was 0.25 (95% CI −0.1, 0.61). However, a subgroup analysis found a significant difference between antidiabetics and placebos in reducing depressive symptoms in Middle Eastern populations, with an SMD of 0.89 (95% CI 0.44, 1.34). Conclusions: The current meta-analysis does not support the efficacy of antidiabetics being superior to the placebo in the treatment of unipolar and bipolar depression. However, a subgroup analysis indicates that patients from the Middle East may benefit from adding an antidiabetic medication to their ongoing medication(s) for their depression. Larger studies with good-quality study designs are warranted. Full article
(This article belongs to the Special Issue Neuropsychopharmacology: Advances, Challenges and Opportunities)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop